This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Gerard Platenburg, PhD
Chief Scientific Officer at ProQR Therapeutics


Gerard is a co-founder and has served as our Chief Scientific Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive background in RNA modulation and orphan drug discovery and development and is currently in charge of our Innovation unit. Gerard has more than twenty-five years of senior managerial experience in growing biotech companies. Prior to joining our company, Gerard worked at Isa Pharmaceuticals B.V. as its Chief Executive Officer. Gerard co-founded Prosensa Holding N.V., growing it to become a well-known clinical stage RNA modulation company, and held various positions including Chief Executive Officer and Chief Development Officer. Gerard also worked at Pharming B.V.. He is a passionate and driven pioneer of early stage technologies. Gerard has a master’s degree in chemistry and molecular biology from Leiden University in 1987 and pursued PhD work at Leiden University. Gerard is currently a board member at Yarrow Biotechnology and a scientific advisory board member at Hybridize Therapeutics.

Agenda Sessions

  • Unlocking the Potential of Innovative Editing Oligonucleotides (EONs) to Address Liver Originated Disorders